$Phathom制药(PHAT)$ $武田制药(TAK)$

PHAT Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarter

P-CAB